

Tom Pike appointed chairman of Clanotech AB's board

STOCKHOLM - January 13, 2011. Clanotech AB, a Karolinska Development portfolio company, today announced that Tom Pike has been elected as Chairman of the board. Tom Pike has many years experience in the life science business and extensive experience in business development.

"We are happy to have Tom Pike as chairman of the board of directors of Clanotech. His background and international experience makes him the ideal person to help us create value and continue the development of Clanotech" says Patrizia Caldirola, CEO of Clanotech AB."

Mr. Pike is actively involved with a number of life science companies and organizations as a consultant and/or board member. His past experience includes Chairman & CEO of Clavis Pharma ASA, a public oncology drug development company, Partner of the venture capital group NeoMed Management and more than 18 years' at Hoffmann-La Roche in Switzerland and Norway where he held a number of positions including CEO, sales and marketing director and business alliance manager. He served on the board (past Chairman) of the Norwegian Association of Pharmaceutical Manufacturers for six years. Mr. Pike is a Norwegian and British citizen and holds a B.Sc. Honours in Pharmacology.

For further information, please contact:

Patrizia Caldirola, CEO, Clanotech AB
Phone +46(0)703747179 E-mail: patrizia.caldirola@clanotech.se

To The Editors

About Clanotech

Clanotech is a privately-held company that discovers and develops pharmaceuticals to treat cancer and age related macular degeneration by targeting biological pathways associated with angiogenesis.

Clanotech is part of the Karolinska Development portfolio. For more information, please visit

<http://www.clanotech.se>

About Karolinska Development

Karolinska Development manages one of the largest portfolios of life science companies in Europe.

Using a unique business model, the company cost efficiently guides the commercialization of world class life science innovations. Since its inception in 2003, Karolinska Development has built a portfolio of some 40 companies. Among the company's projects, 12 candidate drugs are undergoing clinical trials and it is estimated that more than 20 substances have first-in-class potential.

www.karolinskadevelopment.com